CPT code 81514 represents a molecular diagnostic laboratory test that uses quantitative real‑time DNA amplification of vaginal fluid to assess six bacterial species and applies an algorithm to indicate a high likelihood of bacterial vaginosis (BV). This test can also report detection of organisms such as Trichomonas vaginalis and Candida species. Nationally, availability of algorithmic molecular BV testing affects diagnostic pathways for vaginitis and has implications for laboratory workflows, clinical decision support, and payer coverage policies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for BV testing, common sites of service for the assay, and typical billing considerations tied to CPT code 81514. The publication outlines where benchmarks and policy updates influence coverage decisions and highlights operational factors laboratories should consider when implementing algorithm-based molecular diagnostics. The content provides concise guidance on what the code represents, how it integrates into clinical care for suspected BV, and the types of payer policy and reimbursement topics stakeholders commonly assess when evaluating use of CPT code 81514.